vs

Side-by-side financial comparison of HYDROFARM HOLDINGS GROUP, INC. (HYFM) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

HYDROFARM HOLDINGS GROUP, INC. is the larger business by last-quarter revenue ($25.1M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -963.9%, a 786.5% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -32.7%). HYDROFARM HOLDINGS GROUP, INC. produced more free cash flow last quarter ($-4.3M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -31.9%).

Hydrofarm Inc. (HYFM) is an American company specializing in the distribution and manufacture of controlled environment agriculture equipment and supplies.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

HYFM vs LAB — Head-to-Head

Bigger by revenue
HYFM
HYFM
1.3× larger
HYFM
$25.1M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+21.2% gap
LAB
-11.5%
-32.7%
HYFM
Higher net margin
LAB
LAB
786.5% more per $
LAB
-177.4%
-963.9%
HYFM
More free cash flow
HYFM
HYFM
$18.8M more FCF
HYFM
$-4.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-31.9%
HYFM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
HYFM
HYFM
LAB
LAB
Revenue
$25.1M
$19.6M
Net Profit
$-242.2M
$-34.7M
Gross Margin
8.5%
48.5%
Operating Margin
-953.8%
-168.5%
Net Margin
-963.9%
-177.4%
Revenue YoY
-32.7%
-11.5%
Net Profit YoY
-1282.7%
-28.8%
EPS (diluted)
$-52.09
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HYFM
HYFM
LAB
LAB
Q4 25
$25.1M
Q3 25
$29.4M
$19.6M
Q2 25
$39.2M
$21.8M
Q1 25
$40.5M
$40.8M
Q4 24
$37.3M
Q3 24
$44.0M
$22.1M
Q2 24
$54.8M
$22.5M
Q1 24
$54.2M
$45.5M
Net Profit
HYFM
HYFM
LAB
LAB
Q4 25
$-242.2M
Q3 25
$-16.4M
$-34.7M
Q2 25
$-16.9M
$-33.5M
Q1 25
$-14.4M
$-26.0M
Q4 24
$-17.5M
Q3 24
$-13.1M
$-26.9M
Q2 24
$-23.4M
$-45.7M
Q1 24
$-12.6M
$-32.2M
Gross Margin
HYFM
HYFM
LAB
LAB
Q4 25
8.5%
Q3 25
11.6%
48.5%
Q2 25
7.1%
48.8%
Q1 25
17.0%
48.4%
Q4 24
4.9%
Q3 24
19.4%
54.9%
Q2 24
19.8%
46.1%
Q1 24
20.2%
53.1%
Operating Margin
HYFM
HYFM
LAB
LAB
Q4 25
-953.8%
Q3 25
-44.1%
-168.5%
Q2 25
-34.0%
-118.1%
Q1 25
-27.1%
-80.8%
Q4 24
-40.5%
Q3 24
-20.5%
-120.9%
Q2 24
-35.3%
-134.5%
Q1 24
-16.1%
-132.2%
Net Margin
HYFM
HYFM
LAB
LAB
Q4 25
-963.9%
Q3 25
-55.8%
-177.4%
Q2 25
-43.0%
-153.7%
Q1 25
-35.5%
-63.8%
Q4 24
-46.9%
Q3 24
-29.9%
-122.0%
Q2 24
-42.8%
-203.3%
Q1 24
-23.3%
-70.6%
EPS (diluted)
HYFM
HYFM
LAB
LAB
Q4 25
$-52.09
Q3 25
$-3.51
$-0.09
Q2 25
$-3.63
$-0.09
Q1 25
$-3.12
$-0.07
Q4 24
$-3.80
Q3 24
$-2.86
$-0.07
Q2 24
$-5.10
$-0.12
Q1 24
$-2.75
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HYFM
HYFM
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$6.3M
$129.4M
Total DebtLower is stronger
$50.0K
Stockholders' EquityBook value
$-63.3M
$399.7M
Total Assets
$123.8M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HYFM
HYFM
LAB
LAB
Q4 25
$6.3M
Q3 25
$10.7M
$129.4M
Q2 25
$11.0M
$158.6M
Q1 25
$13.7M
$150.9M
Q4 24
$26.1M
Q3 24
$24.4M
$210.6M
Q2 24
$30.3M
$269.8M
Q1 24
$24.2M
$287.1M
Total Debt
HYFM
HYFM
LAB
LAB
Q4 25
$50.0K
Q3 25
$111.7M
Q2 25
$111.6M
Q1 25
$110.0M
Q4 24
$114.7M
Q3 24
$114.8M
$55.2M
Q2 24
$114.9M
$55.1M
Q1 24
$115.4M
$55.0M
Stockholders' Equity
HYFM
HYFM
LAB
LAB
Q4 25
$-63.3M
Q3 25
$178.3M
$399.7M
Q2 25
$195.0M
$424.5M
Q1 25
$209.9M
$454.6M
Q4 24
$223.7M
Q3 24
$243.0M
$489.3M
Q2 24
$255.0M
$510.3M
Q1 24
$278.0M
$577.3M
Total Assets
HYFM
HYFM
LAB
LAB
Q4 25
$123.8M
Q3 25
$369.7M
$539.6M
Q2 25
$389.9M
$557.0M
Q1 25
$410.6M
$579.6M
Q4 24
$426.1M
Q3 24
$445.9M
$681.5M
Q2 24
$463.4M
$708.7M
Q1 24
$494.0M
$777.7M
Debt / Equity
HYFM
HYFM
LAB
LAB
Q4 25
Q3 25
0.63×
Q2 25
0.57×
Q1 25
0.52×
Q4 24
0.51×
Q3 24
0.47×
0.11×
Q2 24
0.45×
0.11×
Q1 24
0.42×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HYFM
HYFM
LAB
LAB
Operating Cash FlowLast quarter
$-4.0M
$-22.2M
Free Cash FlowOCF − Capex
$-4.3M
$-23.1M
FCF MarginFCF / Revenue
-17.1%
-118.1%
Capex IntensityCapex / Revenue
1.3%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.1M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HYFM
HYFM
LAB
LAB
Q4 25
$-4.0M
Q3 25
$-37.0K
$-22.2M
Q2 25
$1.7M
$-20.7M
Q1 25
$-11.8M
$-30.3M
Q4 24
$2.7M
Q3 24
$-4.5M
$-27.9M
Q2 24
$3.8M
$-39.0M
Q1 24
$-2.3M
$-62.5M
Free Cash Flow
HYFM
HYFM
LAB
LAB
Q4 25
$-4.3M
Q3 25
$-207.0K
$-23.1M
Q2 25
$1.4M
$-22.6M
Q1 25
$-12.0M
$-35.3M
Q4 24
$2.4M
Q3 24
$-5.3M
$-30.1M
Q2 24
$3.4M
$-41.0M
Q1 24
$-3.7M
$-63.3M
FCF Margin
HYFM
HYFM
LAB
LAB
Q4 25
-17.1%
Q3 25
-0.7%
-118.1%
Q2 25
3.7%
-103.6%
Q1 25
-29.6%
-86.6%
Q4 24
6.4%
Q3 24
-12.0%
-136.4%
Q2 24
6.2%
-182.2%
Q1 24
-6.9%
-138.9%
Capex Intensity
HYFM
HYFM
LAB
LAB
Q4 25
1.3%
Q3 25
0.6%
4.5%
Q2 25
0.7%
8.7%
Q1 25
0.6%
12.4%
Q4 24
0.7%
Q3 24
1.8%
10.2%
Q2 24
0.7%
8.6%
Q1 24
2.7%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HYFM
HYFM

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons